Gunnel Tybring

Publications
CV
Public outreach and news

Articles

Article: CLINICAL CHEMISTRY AND LABORATORY MEDICINE. 2018;56(7):1054-1062
IL8 and IL16 levels indicate serum and plasma quality
Kofanova O; Henry E; Aguilar Quesada R; Bulla A; Navarro Linares H; Lescuyer P; Shea K; Stone M; Tybring G; Bellora C; Betsou F
Article: CLINICAL CHEMISTRY AND LABORATORY MEDICINE. 2018;56(4):582-594
Strong impact on plasma protein profiles by precentrifugation delay but not by repeated freeze-thaw cycles, as analyzed using multiplex proximity extension assays
Shen Q; Bjorkesten J; Galli J; Ekman D; Broberg J; Nordberg N; Tillander A; Kamali-Moghaddam M; Tybring G; Landegren U
Article: BIOPRESERVATION AND BIOBANKING. 2018;16(1):9-12
Standard PREanalytical Code version 3.0
Betsou F; Bilbao R; Case J; Chuaqui R; Clements JA; De Souza Y; De Wilde A; Geiger J; Grizzle W; Guadagni F; Gunter E; Heil S; Kiehntopf M; Koppandi I; Lehmann S; Linsen L; Mackenzie-Dodds J; Aguilar Quesada R; Tebbakha R; Selander T; Shea K; Sobel M; Somiari S; Spyropoulos D; Stone M; Tybring G; Valyi-Nagy K; Wadhwa L
Article: BIOINFORMATICS. 2017;33(22):3567-3574
Prediction and modeling of pre-analytical sampling errors as a strategy to improve plasma NMR metabolomics data
Brunius C; Pedersen A; Malmodin D; Karlsson BG; Andersson LI; Tybring G; Landberg R
Article: BIOPRESERVATION AND BIOBANKING. 2016;14(5):416-423
Metabolomic Quality Assessment of EDTA Plasma and Serum Samples
Malm L; Tybring G; Moritz T; Landin B; Galli J
Article: BIOPRESERVATION AND BIOBANKING. 2016;14(5):429-439
A Biospecimen Proficiency Testing Program for Biobank Accreditation: Four Years of Experience
Gaignaux A; Ashton G; Coppola D; De Souza Y; De Wilde A; Eliason J; Grizzle W; Guadagni F; Gunter E; Koppandi I; Shea K; Shi T; Stein JA; Sobel ME; Tybring G; Van den Eynden G; Betsou F
Article: BIOPRESERVATION AND BIOBANKING. 2016;14(5):440-446
Practical Approach to Biobanking in Zimbabwe: Establishment of an Inclusive Stakeholder Framework
Matimba A; Tybring G; Chitereka J; Zinyama-Gutsire R; Dandara C; Buren E; Dhoro M; Masimirembwa C
Article: BIOPRESERVATION AND BIOBANKING. 2016;14(5):398-409
Assays for Qualification and Quality Stratification of Clinical Biospecimens Used in Research: A Technical Report from the ISBER Biospecimen Science Working Group
Betsou F; Bulla A; Cho SY; Clements J; Chuaqui R; Coppola D; De Souza Y; De Wilde A; Grizzle W; Guadagni F; Gunter E; Heil S; Hodgkinson V; Kessler J; Kiehntopf M; Kim HS; Koppandi I; Shea K; Singh R; Sobel M; Somiari S; Spyropoulos D; Stone M; Tybring G; Valyi-Nagy K; Van den Eynden G; Wadhwa L
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2015;71(4):433-439
CYP2C19*17 affects R-warfarin plasma clearance and warfarin INR/dose ratio in patients on stable warfarin maintenance therapy
Chang M; Soderberg MM; Scordo MG; Tybring G; Dahl M-L
Article: BIOPRESERVATION AND BIOBANKING. 2014;12(2):154-160
The Research Biobank of the Year Competition of the European, Middle Eastern and African Society for Biopreservation and Biobanking (ESBB): Aims and Achievements
Schroeder C; Corfield J; di Donato J-H; Meir K; Parodi B; Schmitz AA; Tiran A; Tybring G; Hewitt RE
Article: JOURNAL OF PROTEOMICS. 2013;95:46-54
Profiling post-centrifugation delay of serum and plasma with antibody bead arrays
Qundos U; Hong M-G; Tybring G; Divers M; Odeberg J; Uhlen M; Nilsson P; Schwenk JM
Article: BIOPRESERVATION AND BIOBANKING. 2012;10(4):366-374
Standard Preanalytical Coding for Biospecimens: Review and Implementation of the Sample PREanalytical Code (SPREC)
Lehmann S; Guadagni F; Moore H; Ashton G; Barnes M; Benson E; Clements J; Koppandi I; Coppola D; Demiroglu SY; DeSouza Y; De Wilde A; Duker J; Eliason J; Glazer B; Harding K; Jeon JP; Kessler J; Kokkat T; Nanni U; Shea K; Skubitz A; Somiari S; Tybring G; Gunter E; Betsou F
Article: GENETIC ENGINEERING AND BIOTECHNOLOGY NEWS. 2012;32(16):1
Biobanking Confronts Growing Pains
Tybring G
Article: EUROPEAN JOURNAL OF EPIDEMIOLOGY. 2011;26(1):67-77
LifeGene--a large prospective population-based study of global relevance.
Almqvist C; Adami H-O; Franks PW; Groop L; Ingelsson E; Kere J; Lissner L; Litton J-E; Maeurer M; Michaëlsson K; Palmgren J; Pershagen G; Ploner A; Sullivan PF; Tybring G; Pedersen NL
Article: BIOPRESERVATION AND BIOBANKING. 2010;8(1):65-69
Laboratory Management of Samples in Biobanks: European Consensus Expert Group Report
Yuille M; Illig T; Hveem K; Schmitz G; Hansen J; Neumaier M; Tybring G; Wichmann E; Ollier B
Article: PHARMACOGENOMICS JOURNAL. 2009;9(3):208-217
Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers
Ghotbi R; Gomez A; Milani L; Tybring G; Syvanen A-C; Bertilsson L; Ingelman-Sundberg M; Aklillu E
Article: TWIN RESEARCH AND HUMAN GENETICS. 2007;10(4):604-625
Large-scale zygosity testing using single nucleotide polymorphisms
Hannelius U; Gherman L; Makela V-V; Lindstedt A; Zucchelli M; Lagerberg C; Tybring G; Kere J; Lindgren CM
Article: CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. 2006;15(9):1742-1745
Quality and quantity of saliva DNA obtained from the self-administrated oragene method -: A pilot study on the cohort of Swedish men
Rylander-Rudqvist T; Hakansson N; Tybring G; Wolk A
Article: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2004;95(3):112-119
Omeprazole treatment of Korean patients: Effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes
Roh HK; Kim PS; Lee DH; Tybring G; Sagar M; Park CS; Seensalu R; Bertilsson L
Article: ENDOCRINOLOGY. 2004;145(4):1972-1979
Female-predominant expression of fatty acid translocase/CD36 in rat and human liver
Ståhlberg N; Rico-Bautista E; Fisher RM; Wu XX; Cheung L; Flores-Morales A; Tybring G; Norstedt G; Tollet-Egnell P
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2003;56(6):679-682
Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity.
Härtter S; Nordmark A; Rose D-M; Bertilsson L; Tybring G; Laine K
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2003;56(4):415-421
Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes
Herrlin K; Yasui-Furukori N; Tybring G; Widén J; Gustafsson LL; Bertilsson L
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2003;56(2):232-237
The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects
Palovaara S; Tybring G; Laine K
Article: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2003;93(2):77-81
A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes
Laine K; Yasar Ü; Widén J; Tybring G
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2003;74(1):32-43
Artemisinin autoinduction is caused by involvement of cytochrome P4502B6 but not 2C9
Simonsson USH; Jansson B; Hai TN; Huong DX; Tybring G; Ashton M
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2003;55(6):630-634
Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians
Dalén P; Dahl ML; Roh HK; Tybring G; Eichelbaum M; Wilkinson GR; Bertilsson L
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2003;59(2):103-109
Bioactivation of cyclophosphamide:: the role of polymorphic CYP2C enzymes
Griskevicius L; Yasar Ü; Sandberg M; Hidestrand M; Eliasson E; Tybring G; Hassan M; Dahl ML
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2003;73(6):517-528
The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes
Christensen M; Andersson K; Dalén P; Mirghani RA; Muirhead GJ; Nordmark A; Tybring G; Wahlberg A; Yasar Ü; Bertilsson L
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2003;59(1):23-28
Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man
Mirghani RA; Ericsson Ö; Tybring G; Gustafsson LL; Bertilsson L
Article: DRUG METABOLISM AND DISPOSITION. 2002;30(12):1368-1371
Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro;: 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway
Mirghani RA; Yasar Ü; Zheng T; Cook JM; Gustafsson LL; Tybring G; Ericsson Ö
Article: XENOBIOTICA. 2002;32(11):985-996
Characterization of testosterone metabolism and 7-hydroxycoumarin conjugation by rat and human liver slices after storage in liquid nitrogen for 1 h up to 6 months
Granhall C; Floby E; Nordmark A; Orzechowski A; Thörne A; Tybring G; Sohlenius-Sternbeck AK
Article: PHARMACEUTICAL RESEARCH. 2002;19(7):1034-1037
The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19
Härtter S; Tybring G; Friedberg T; Weigmann H; Hiemke C
Article: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. 2002;25(5):459-462
Does hepatic metabolism of melatonin affect the endogenous serum melatonin level in man?
Ursing C; Härtter S; von Bahr C; Tybring G; Bertilsson L; Röjdmark S
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2002;71(3):141-152
Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19)
Christensen M; Tybring G; Mihara K; Yasui-Furokori N; Carrillo JA; Ramos SI; Andersson K; Dahl ML; Bertilsson L
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2001;57(10):729-735
The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro
Yasar Ü; Eliasson E; Forslund-Bergengren C; Tybring G; Gadd M; Sjöqvist F; Dahl ML
Article: DRUG METABOLISM AND DISPOSITION. 2001;29(10):1263-1268
Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes
Yasui-Furukori N; Hidestrand M; Spina E; Facciolá G; Scordo MG; Tybring G
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2001;70(4):327-335
Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Article: DRUG METABOLISM AND DISPOSITION. 2001;29(7):1051-1056
Role of CYP2C9 polymorphism in losartan oxidation
Yasar Ü; Tybring G; Hidestrand M; Oscarson M; Ingelman-Sundberg M; Dahl ML; Eliasson E
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2001;70(1):10-16
Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo:: A pilot study
Härtter S; Ursing C; Morita S; Tybring G; von Bahr C; Christensen M; Röjdmark S; Bertilsson L
Article: THERAPEUTIC DRUG MONITORING. 2001;23(3):282-286
Determination of exogenous melatonin and its 6-hydroxy metabolite in human plasma by liquid chromatography-mass spectrometry
Härtter S; Morita S; Bodin K; Ursing C; Tybring G; Bertilsson L
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2001;56(12):881-888
Cytochrome P₄₅₀ isoforms involved in melatonin metabolism in human liver microsomes
Facciolá G; Hidestrand M; von Bahr C; Tybring G
Article: GASTROENTEROLOGY. 2000;119(3):670-676
Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism
Sagar M; Tybring G; Dahl ML; Bertilsson L; Seensalu R
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2000;68(2):151-159
No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects
Laine K; Tybring G; Bertilsson L
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2000;56(2):123-127
Fluvoxamine but not citalopram increases serum melatonin in healthy subjects -: an indication that cytochrome P₄₅₀ CYP1A2 and CYP2C19 hydroxylate melatonin
von Bahr C; Ursing C; Yasui N; Tybring G; Bertilsson L; Röjdmark S
Article: FUNDAMENTAL & CLINICAL PHARMACOLOGY. 1999;13(6):671-675
Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19
Mihara K; Svensson USH; Tybring G; Hai TN; Bertilsson L; Ashton M
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 1998;33(10):1034-1038
CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection
Sagar M; Seensalu R; Tybring G; Dahl ML; Bertilsson L
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 1998;64(4):391-401
Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype
Herrlin K; Massele AY; Jande M; Alm C; Tybring G; Abdi YA; Wennerholm A; Johansson I; Dahl ML; Bertilsson L; Gustafsson LL
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 1998;64(4):384-390
Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes
Yue QY; Zhong ZH; Tybring G; Dalén P; Dahl ML; Bertilsson L; Sjöqvist F
Article: JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES. 1998;716(1-2):382-386
High-performance liquid chromatography-mass spectrometry for the quantification of nortriptyline and 10-hydroxynortriptyline in plasma.
Tybring G; Nordin J; Widén J
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 1998;53(5):347-349
Correlation between steady-state plasma concentrations of mianserin and trazodone in depressed patients.
Otani K; Tybring G; Mihara K; Yasui N; Kaneko S; Ohkubo T; Nagasaki T; Sugawara K
Article: JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY. 1997;17(6):467-471.
The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients
Mihara K; Otani K; Tybring G; Dahl ML; Bertilsson L; Kaneko S
Article: PHARMACOGENETICS AND GENOMICS. 1997;7(5):369-374
Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite, desmethylmianserin, in depressed Japanese patients
Yasui N; Tybring G; Otani K; Mihara K; Suzuki A; Svensson JO; Kaneko S
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 1997;62(4):384-391
Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin
Bottiger Y; Tybring G; Gotharson E; Bertilsson L
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 1997;44(2):186-189
Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19
Bertilsson L; Tybring G; Widen J; Chang M; Tomson T
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 1997;62(2):129-137
Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects
Tybring G; Bottiger Y; Widen J; Bertilsson L
Article: PHARMACOGENETICS AND GENOMICS. 1996;6(6):547-551
CYP2C19 genotype and phenotype determined by omeprazole in a Korean population
Roh HK; Dahl ML; Tybring G; Yamada H; Cha YN; Bertilsson L
Article: PHARMACOGENETICS AND GENOMICS. 1995;5(6):358-363
Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype
Chang M; Dahl ML; Tybring G; Gotharson E; Bertilsson L
Article: THERAPEUTIC DRUG MONITORING. 1995;17(5):516-521
ENANTIOSELECTIVE DETERMINATION OF MIANSERIN AND ITS DESMETHYL METABOLITE IN PLASMA DURING TREATMENT OF DEPRESSED JAPANESE PATIENTS
TYBRING G; OTANI K; KANEKO S; MIHARA K; FUKUSHIMA Y; BERTILSSON L
Show more

All other publications

Letter: CLINICAL PHARMACOKINETICS. 2015;54(3):321
Quantitative Methods for Prediction of the Effect of Cytochrome P450 Gene Polymorphisms on Substrate Drug Exposure: Authors' Reply
Lindh JD; Chang M; Tybring G; Dahl M-L
Review: CLINICAL PHARMACOKINETICS. 2014;53(9):801-811
Impact of Cytochrome P450 2C19 Polymorphisms on Citalopram/Escitalopram Exposure: A Systematic Review and Meta-Analysis
Chang M; Tybring G; Dahl M-L; Lindh JD
Published conference paper: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2004;60(3):173-182
Identification of cytochromes P₄₅₀ 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro
Ufer M; Svensson JO; Krausz KW; Gelboin HV; Rane A; Tybring G
Published conference paper: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2002;71(1):89-98
Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CΥP2C9 genotype
Yasar Ü; Forslund-Bergengren C; Tybring G; Dorado P; Llerena A; Sjöqvist F; Eliasson E; Dahl ML
Published conference paper: ACTA PSYCHIATRICA SCANDINAVICA, SUPPLEMENT. 1997;96:14-21
Pharmacogenetics of antidepressants: Clinical aspects
Bertilsson L; Dahl ML; Tybring G
Thesis / dissertation: 1996
Enantioselective drug metabolism catalysed by the polymorphic CYP2D6 and CYP2C19 : a methodological investigation focused on mianserin, mephenytoin and omeprazole
Tybring, Gunnel

Employments

Consultant/Hired Personnel, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 2025-2025

Degrees and Education

Docent, Karolinska Institutet, 2001

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI